Women's Health

About 72% of the observed pregnancies after allogeneic hematopoietic cell transplantation occurred spontaneously, whereas remaining pregnancies were a result of assisted reproductive activities.

Investigators reported that more than half of individuals had great knowledge about protecting themselves from COVID-19.

The researchers estimate that pregnancy losses because of malaria and parasitemia risk before conception was reduced by 65% to 86%.

The authors also found that there was a higher frequency of miscarriages compared with women who did not have asthma.

Additionally, the authors are concerned by the lack of increase in depressive or anxiety diagnoses, indicating potential barriers to care.

Pharmacists’ role in community-based cancer centers are expanding, with a more significant role in treatment plan selection, education, collaboration to create individualized care plans, managing adverse effects, and aiding with financial toxicities.

The study authors suggest that annual screening for women aged 40 and older may be beneficial, but warn of the increased risk of false positive results.

There is no significant impact on maternal or infant health outcomes when taking an additional iron supplement

Intravenous immunoglobulin (IVIG) therapy was found to have statistically significant positive effects on live birth rates, implantation rate, and other indicators.

The authors stress that health care providers should explain false positive results to their patients, reassure them that results may be negative, and stress the significance of continued screenings.

For those with unexplained pregnancy loss, these results could prove promising improvements to birth outcomes.

Women's health extends beyond reproductive health, yet much of the research in women's health focuses on these "below the belt" health issues, despite data showing that women disproportionately suffer from certain health conditions, such as heart failure.

The author suggest how to improve the representation of women, older adults, and minorities in clinical research that will require effort from a broad range of stakeholders.

Nurx reproductive access survey reveals 28% of women do not believe their right to contraception is protected.

The updates are based on nationwide reports of extreme pain during IUD insertion.

Pharmacists play an important role in managing patients with this complex condition.

Investigators will examine the combination with pembrolizumab and lenvatinib in patients with HER2-expressing endometrial cancer.

The RUBY trial will continue and analyze the overall population survival after treatment with the drug combination.

Pharmacists can help patients with polycystic ovary syndrome safely incorporate complementary supplements, such as cinnamon, into their treatment plan.

An extension of a long-acting cabotegravir study shows safety prior to and during pregnancy in cisgender women, with full results being presented at the 2024 International AIDS Conference.

The decision offers patients with difficulty swallowing their medication expanded options for treatment administration.

Study investigators surveyed nearly 200 women on their concern around period-tracking apps’ data practices, as well as whether Roe v Wade being overturned influenced their concerns.

Increased awareness of women's cardiovascular health and the impact of estrogen fluctuation throughout women’s lives on cardiovascular disease could both boost the economy and improve health outcomes.

Fish are rich in nutrients that aid in brain development, and the model can help provide more guidance for pregnant individuals when consuming seafood.

Additionally, birth weight was higher in babies born to mothers who were prescribed glucagon-like peptide-1 (GLP-1) medications either 90 days prior to pregnancy or during the first trimester.

Perinatal depression increases the risk of cardiovascular disease in women.

Tepylute is a ready-to-dilute, injectable formula that reduces preparation time and enable dosing accuracy.

Reducing maternal mortality through improving access, screening, education and providing support during pregnancy.

The indication is for adult patients with primary advanced or recurrent endometrial carcinoma and is the third indication that pembrolizumab has received for this disease state.

Durvalumab plus carboplatin and paclitaxel, continued with durvalumab monotherapy, decreased the risk of disease progression or death by 58%.